Paul is a top-tier Biotechnology Investigator and Executive with extensive strategic and leadership experience and demonstrated success in bench to IND development of small molecule and biologic drugs for oncology, autoimmunity, chronic inflammation and fibrosis. Paul has deep experience in therapeutic area analysis and strategic development, opportunity assessment, due diligence, and alignment of research, commercial and clinical strategies. His recent accomplishments include working intensively with CoStim Pharmaceuticals’ executive team to prioritize and launch that company’s Cancer Immunotherapeutics portfolio. More recently Paul embedded with X-Chem Inc to create X-Rx Discovery, an asset-centric biotechnology company. As CSO, Pual built that company from conception to full portfolio execution, including medicinal chemistry, assay development, ADME/DMPK support, efficacy and toxicity assessment. Paul drove two lead programs, targeting autotaxin and BTK, from hit through lead optimization, and selected lead candidates for IND enablement